Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
| SHPCX Fund | USD 13.85 0.04 0.29% |
Slightly above 55% of Health Biotchnology's investor base is interested to short. The analysis of overall sentiment of trading Health Biotchnology Portfolio mutual fund suggests that many investors are impartial at this time. Health Biotchnology's investing sentiment can be driven by a variety of factors including economic data, Health Biotchnology's earnings reports, geopolitical events, and overall market trends.
Health |
Phase 3 trial of Biogen and UCBs dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here.
Read at seekingalpha.com
 |
Health Biotchnology Fundamental Analysis
We analyze Health Biotchnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Health Biotchnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Health Biotchnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Health Biotchnology is currently under evaluation in price to earning among similar funds. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Health Biotchnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Health Biotchnology mutual fund to make a market-neutral strategy. Peer analysis of Health Biotchnology could also be used in its relative valuation, which is a method of valuing Health Biotchnology by comparing valuation metrics with similar companies.
Peers
Health Biotchnology Related Equities
| JQLAX | Multimanager Lifestyle | 0.52 | ||||
| APHFX | Artisan High | 0.11 | ||||
| AGTFX | Morningstar Aggressive | 0.06 | ||||
| MWHIX | Metropolitan West | 0.11 | ||||
| PHYPX | Pace High | 0.11 | ||||
| SGYAX | Siit High | 0.14 |
Other Information on Investing in Health Mutual Fund
Health Biotchnology financial ratios help investors to determine whether Health Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Health with respect to the benefits of owning Health Biotchnology security.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |